Cargando…

Quantification of minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL) using amplicon-fusion-site polymerase chain reaction (AFS-PCR)

The amplification of putative oncogenes is a common finding within the genome of various cancer types. Identification and further targeting of specific junction sites within the sequence of genomic amplicons (amplicon fusion sites, AFS) by PCR (AFS-PCR) is suitable for quantification of minimal resi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weber, Axel, Taube, Sylvia, zur Stadt, Udo, Horstmann, Martin, Krohn, Knut, Bradtke, Jutta, Teigler-Schlegel, Andrea, Leiblein, Sabine, Christiansen, Holger
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518178/ https://www.ncbi.nlm.nih.gov/pubmed/23210797 http://dx.doi.org/10.1186/2162-3619-1-33

Ejemplares similares

Characterization of novel, recurrent genomic rearrangements as sensitive MRD targets in childhood B-cell precursor ALL
por: zur Stadt, Udo, et al.
Publicado: (2019)

ABL-class Genomic Breakpoint Q-PCR: A Patient-specific Approach for MRD Monitoring in Acute Lymphoblastic Leukemia
por: van Outersterp, Inge, et al.
Publicado: (2023)

MicroRNAs Distinguish Cytogenetic Subgroups in Pediatric AML and Contribute to Complex Regulatory Networks in AML-Relevant Pathways
por: Daschkey, Svenja, et al.
Publicado: (2013)

Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions: towards MRD for all
por: Kuiper, Roland P., et al.
Publicado: (2021)

COBL is a novel hotspot for IKZF1 deletions in childhood acute lymphoblastic leukemia
por: Lopes, Bruno Almeida, et al.
Publicado: (2016)

Clofarabine increases the eradication of minimal residual disease of primary B-precursor acute lymphoblastic leukemia compared to high-dose cytarabine without improvement of outcome. Results from the randomized clinical trial 08-09 of the Cooperative Acute Lymphoblastic Leukemia Study Group.
por: Escherich, Gabriele, et al.
Publicado: (2021)

Consensus Recommendations for MRD Testing in Adult B-Cell Acute Lymphoblastic Leukemia in Ontario
por: Tierens, Anne, et al.
Publicado: (2021)

Characterization of IG-MYC-breakpoints and their application for quantitative minimal disease monitoring in high-risk pediatric Burkitt-lymphoma and -leukemia
por: Möker, Paula, et al.
Publicado: (2022)

PAX5-AUTS2: A recurrent fusion gene in childhood B-cell precursor acute lymphoblastic leukemia
por: Denk, Dagmar, et al.
Publicado: (2012)

Genomic Imbalances Are Confined to Non-Proliferating Cells in Paediatric Patients with Acute Myeloid Leukaemia and a Normal or Incomplete Karyotype
por: Ballabio, Erica, et al.
Publicado: (2011)

Prognostic value of low-level MRD in adult acute lymphoblastic leukemia detected by low- and high-throughput methods
por: Kotrová, Michaela, et al.
Publicado: (2022)

Survival outcomes in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia treated with blinatumomab
por: Kantarjian, Hagop M., et al.
Publicado: (2023)

Measurable Residual Disease (MRD) by Flow Cytometry in Adult B-Acute Lymphoblastic Leukaemia (B-ALL) and Acute Myeloid Leukaemia (AML): Correlation with Molecular MRD Testing and Clinical Outcome at One Year
por: van der Linde, Riana, et al.
Publicado: (2023)

411 Mrd. €, 11,9 %
por: Kuhn, Joseph
Publicado: (2022)

Computer aided analysis of additional chromosome aberrations in Philadelphia chromosome positive acute lymphoblastic leukaemia using a simplified computer readable cytogenetic notation
por: Bradtke, Jutta, et al.
Publicado: (2003)

MRD in AML: The Role of New Techniques
por: Voso, Maria Teresa, et al.
Publicado: (2019)

HOW TO INCORPORATE MRD IN CLINICAL TRIALS
por: San-Miguel, Jesus
Publicado: (2022)

NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on an MRD-based protocol
por: Svaton, Michael, et al.
Publicado: (2023)

Neonatal Acute Lymphoblastic Leukemia with t(9;11) Translocation Presenting as Blueberry Muffin Baby: Successful Treatment by ALL-BFM Induction Therapy, Allogeneic Stem Cell Transplantation from an Unrelated Donor, and PCR-MRD-Guided Post-Transplant Follow-Up
por: Schlegel, Simon, et al.
Publicado: (2020)

Detection of DNA Amplicons of Polymerase Chain Reaction Using Litmus Test
por: Chang, Dingran, et al.
Publicado: (2017)

IKZF1 Deletions with COBL Breakpoints Are Not Driven by RAG-Mediated Recombination Events in Acute Lymphoblastic Leukemia
por: Lopes, Bruno A., et al.
Publicado: (2019)

Droplet Digital PCR Improves IG-/TR-based MRD Risk Definition in Childhood B-cell Precursor Acute Lymphoblastic Leukemia
por: Della Starza, Irene, et al.
Publicado: (2021)

Pediatric T-cell acute lymphoblastic leukemia blast signature and MRD associated immune environment changes defined by single cell transcriptomics analysis
por: Bhasin, Swati S., et al.
Publicado: (2023)

P390: ALLO-HSCT OR CHEMOTHERAPY FOR B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA IN THE FIRST COMPLETE REMISSION: IMPACT OF MRD AND IKZF1
por: Deng, Shiyu, et al.
Publicado: (2023)

Vidjil add‐on for MRD quantification of samples processed using the EuroClonality‐NGS protocol
por: Giusti, Guilherme Navarro Nilo, et al.
Publicado: (2023)

Mutations in cell elongation genes mreB, mrdA and mrdB suppress the shape defect of RodZ-deficient cells
por: Shiomi, Daisuke, et al.
Publicado: (2013)

Is Quantification of Measurable Clonal Plasma Cells in Stem Cell Grafts (gMRD) Clinically Meaningful?
por: Cengiz Seval, Guldane, et al.
Publicado: (2022)

Genomic and transcriptional landscape of P2RY8-CRLF2-positive childhood acute lymphoblastic leukemia
por: Vesely, C, et al.
Publicado: (2017)

Identification of germline susceptibility loci in ETV6-RUNX1-rearranged childhood acute lymphoblastic leukemia
por: Ellinghaus, E, et al.
Publicado: (2012)

MRD in multiple myeloma: more questions than answers?
por: Moreau, Philippe, et al.
Publicado: (2017)

SERS-Based Assessment of MRD in Acute Promyelocytic Leukemia?
por: Turcas, Cristina, et al.
Publicado: (2020)

NP-MRD: the Natural Products Magnetic Resonance Database
por: Wishart, David S, et al.
Publicado: (2021)

MRD negativity: considerations for older adults with multiple myeloma
por: Mian, Hira, et al.
Publicado: (2023)

KRAS and CREBBP mutations: a relapse-linked malicious liaison in childhood high hyperdiploid acute lymphoblastic leukemia
por: Malinowska-Ozdowy, K, et al.
Publicado: (2015)

P889: WILL OUTCOME IMPROVE BY TREATING MULTIPLE MYELOMA PATIENTS AT MRD RELAPSE? THE REMNANT STUDY (RELAPSE FROM MRD NEGATIVITY AS INDICATION FOR TREATMENT)
por: Askeland, F. B., et al.
Publicado: (2022)

FLT3-ITD in Children with Early T-cell Precursor (ETP) Acute Lymphoblastic Leukemia: Incidence and Potential Target for Monitoring Minimal Residual Disease (MRD)
por: Lo Nigro, Luca, et al.
Publicado: (2022)

Bone Marrow Stromal Cell Regeneration Profile in Treated B-Cell Precursor Acute Lymphoblastic Leukemia Patients: Association with MRD Status and Patient Outcome
por: Oliveira, Elen, et al.
Publicado: (2022)

PAX5 fusion genes in t(7;9)(q11.2;p13) leukemia: a case report and review of the literature
por: Denk, Dagmar, et al.
Publicado: (2014)

Early vs. late MRD response- and risk-based treatment intensification of childhood acute lymphoblastic leukemia: a prospective pilot study from Saudi Arabia
por: Jastaniah, Wasil, et al.
Publicado: (2018)

Potential and pitfalls of whole transcriptome-based immunogenetic marker identification in acute lymphoblastic leukemia; a EuroMRD and EuroClonality-NGS Working Group study
por: van der Velden, Vincent H. J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_urthg22f4np9gt9tclguug4bea